drugset / Trial / NCT04612712
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
Phase 1/2
Terminated
15 enrolled
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · collab
NaSequentialOpen-labelTreatment
Summary
This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of Donafenib combined with KN046 in subjects with Advanced Gastrointestinal Tumors.
Timeline
- Start
- 2021-01-19
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 50 mg | Oral |
| Subject | Donafenib | Small molecule | 100 mg | Oral |
| Subject | Donafenib | Small molecule | 200 mg | Oral |
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | Intravenous |
Indications
No indication recorded.